Suppr超能文献

[病毒性慢性活动性肝病患者的免疫纠正疗法]

[Immunocorrective therapy of patients with chronic active liver diseases of a viral nature].

作者信息

Mansurov Kh Kh, Asfandiiarova N S, Nikolaeva O S, Mansurova F Kh, Rasunova T Kh

出版信息

Ter Arkh. 1987;59(2):114-7.

PMID:3495044
Abstract

A study of the effect of immunocorrective drugs on the clinicobiochemical and immunological indices of patients with chronic active liver diseases of viral nature made it possible to work out criteria for administration of levamisole (the absence of the cytolytic syndrome, the presence of immunodeficiency in the system of cellular immunity and disturbance of immunoregulation), prednisolone, the combination of prednisolone and azathioprine, and d-Penicillamine (severe hepatocellular insufficiency, the presence of autoimmune reactions and disturbance of immunoregulation). The treatment of patients with chronic active diseases with immunocorrective drugs required a strict individual approach taking account of clinicobiochemical, immunological and morphological indices.

摘要

一项关于免疫纠正药物对病毒性慢性活动性肝病患者临床生化和免疫指标影响的研究,使得制定左旋咪唑(不存在细胞溶解综合征、细胞免疫系统存在免疫缺陷及免疫调节紊乱)、泼尼松龙、泼尼松龙与硫唑嘌呤联合用药以及青霉胺(严重肝细胞功能不全、存在自身免疫反应及免疫调节紊乱)的给药标准成为可能。使用免疫纠正药物治疗慢性活动性疾病患者需要严格的个体化方法,要考虑临床生化、免疫和形态学指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验